Alogliptin Tablet, Film Coated
Product Images NDC 45802-150

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alogliptin (NDC 45802-150). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Padagis Israel Pharmaceuticals Ltd, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Alogliptin 01)

Chemical structure of Alogliptin shown with molecular groups, including a cyanophenyl moiety, an amino group attached to a piperidine ring, and a benzoic acid residue indicated separately.*

FDA Label Image

Figure 1 (Alogliptin 02)

A forest plot graph comparing the pharmacokinetic ratio (AUC and Cmax) of Alogliptin when coadministered with various drugs metabolized by different CYP enzymes and transporters (Renally Excreted, CYP1A2, CYP2C8, CYP2C9, CYP2D6, CYP3A4, Pgp substrates). The graph includes ratio points with 90% confidence intervals and corresponding dosage recommendations, all indicating no dose adjustment needed.*

FDA Label Image

Figure 2 (Alogliptin 03)

A pharmacokinetic (PK) drug interaction chart showing the ratio and 90% confidence intervals of Alogliptin exposure (AUC and Cmax) when coadministered with various drugs, compared to Alogliptin alone. The chart includes drugs grouped by renal excretion, CYP2C8/9 and CYP3A4 inhibitors, and Pgp inhibitors and substrates, with a ‘No dose adjustment’ recommendation for all listed interactions.*

FDA Label Image

Figure 3 (Alogliptin 04)

A bar graph comparing the least squares mean change in A1C percentage among different treatment groups: placebo, Alogliptin (25 mg), Pioglitazone (15 mg, 30 mg, 45 mg), and combinations of Alogliptin with Pioglitazone at various doses. The baseline mean A1C is 8.5-8.6. Bars show reductions in A1C values for each group, with combination treatments showing the greatest decreases.*

FDA Label Image

Figure 4 (Alogliptin 05)

A Kaplan-Meier curve displaying cumulative event probability over 30 months from randomization, comparing Alogliptin (NESINA) versus placebo. The solid line represents placebo, and the dotted line represents NESINA, with event probabilities increasing over time. The graph includes numbers at risk for each group at various time points and a hazard ratio with confidence interval indicating comparison between groups.*

FDA Label Image

Principal Display Panel (6.25 mg Tablet Bottle Label)

Label for Alogliptin Tablets 6.25 mg film-coated tablets, containing 8.5 mg alogliptin benzoate equivalent to 6.25 mg alogliptin. The label indicates a 30-tablet count, distributed by Perrigo in Allegan, MI. It includes storage instructions at 25°C with excursions allowed between 15°-30°C and a note to dispense with medication guide.*

FDA Label Image

Principal Display Panel (12.5 mg Tablet Bottle Label)

Label for Alogliptin Tablets 12.5 mg film-coated tablets, in a 30-tablet package. The label includes the NDC 45802-103-65, a note to dispense with a medication guide, storage instructions at 25°C with allowed excursions, and distribution by Perrigo. The label emphasizes safety warnings such as accepting only if the seal is intact and keeping out of reach of children.*

FDA Label Image

Principal Display Panel (25 mg Tablet Bottle Label)

Label for Alogliptin 25 mg tablets, film-coated, oral dosage form. The label shows 30 tablets per container and includes directions to dispense with a medication guide. It is labeled as Rx only and distributed by Perrigo, with storage instructions and a barcode visible. The strength highlighted is 25 mg of alogliptin per tablet.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.